Leukocytoclastic vasculitis
ICD-10 L95.9 · ICD-11 4A44.B0

Leukocytoclastic Vasculitis with Systemic Organ Involvement When Prednisone Has Not Achieved Disease Remission

This protocol applies to leukocytoclastic vasculitis (LCV) presenting with systemic organ involvement — including ANCA-associated vasculitis, cryoglobulinemic vasculitis, IgA vasculitis, hypocomplementemic urticarial vasculitis, and connective tissue disease — where prior corticosteroid therapy has not led to disease remission.

Clinical Scenario

When LCV arises in the setting of a systemic vasculitis or underlying connective tissue disease, the management approach must account for the severity of organ involvement and the specific associated condition. Entities in this group — ANCA-associated vasculitis, cryoglobulinemic vasculitis, IgA vasculitis, hypocomplementemic urticarial vasculitis, and connective tissue disease — each carry distinct implications for treatment intensity.

Prior Treatment Line — Remission Not Achieved

The initial approach with prednisone did not achieve the goal of disease remission in this setting. This protocol describes the structured next step for patients in whom corticosteroid therapy alone has proven insufficient.

Next-Step Approach (Partial Overview)

When remission has not been reached with prednisone in LCV with systemic involvement, the protocol moves to immunosuppressive agents — specifically oral antimetabolite-class medications — selected and balanced according to individual risk and benefit.

Treatment goal: disease remission. Full regimen, agent selection, and sequencing are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/rheumatology/keac115

Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease.

When LCV occurs in the context of a systemic vasculitis or an underlying disease, or if none of the above-mentioned agents is effective or tolerated, immunosuppressive medications, such as azathioprine (1–2 mg/kg/day, if thiopurine methyltransferase levels are normal), methotrexate (0.2–0.3 mg/kg/week), with folic acid supplementation, and mycophenolate mofetil (2–3 g/day) can be considered, balancing risks and benefits.

View source ↗